AIM ImmunoTech said that it has extended a 2020 agreement with Shenzhen Smoore Technology related to development of an inhaled version of its Ampligen rintatolimod for the treatment of COVID-19. The agreement with Smoore is for the use of a Smoore-designed "personal inhalation device designed to administer Ampligen, given temperature parameters of dsRNA." According to … [Read more...] about AIM Immunotech extends deal with Smoore related to development of inhaled Ampligen
Business
Inhalon Biopharma gets US Army contract for development of inhaled antibody for the treatment of COVID-19
According to North Carolina-based startup Inhalon Biopharma, the US Army Medical Research & Development Command (USAMRDC) has awarded the company a contract worth $7 million for a Phase 1/2a study of its IN-006 inhaled neutralizing monoclonal antibody for the treatment of COVID-19 in an outpatient setting. The company expects topline results to be available in … [Read more...] about Inhalon Biopharma gets US Army contract for development of inhaled antibody for the treatment of COVID-19
Vectura to be acquired by the Carlyle Group
A newly formed company called Murano Bidco, which is controlled by the Carlyle Group, has agreed to pay approximately £958 million to acquire inhalation CDMO Vectura, the companies have announced. According to the announcement, Bidco was formed specifically for the purpose of acquiring Vectura. Vectura Chairman Bruno Angelici commented, "Vectura has made strong … [Read more...] about Vectura to be acquired by the Carlyle Group
GSK sells its stake in Innoviva
Innoviva is buying back GlaxoSmithKline's entire stake in the company, a total of 32 million shares (~ 32% of company). Innoviva (formerly Theravance, Inc.), was spun off from Theravance in 2013 to manage the royalties from dry powder inhalers that Theravance developed in partnership with GSK, including Relvar/Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta. GSK will … [Read more...] about GSK sells its stake in Innoviva
Iconovo announces deal with Respiratorius for development of DPI
Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3 million, the company said. The project, which involves development of Respiratorius's RES030-085 for the treatment of COPD and severe asthma, would lead to a license agreement if … [Read more...] about Iconovo announces deal with Respiratorius for development of DPI
Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST
Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone's etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing will pay $15 million up front and up to $107.5 million in milestone and … [Read more...] about Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST
Akroswiss gets funding for development of midazolam nasal spray
Swiss start-up Akroswiss has announced that it raised "several million Swiss Franc" for development of the company's midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include Linsi, Bernhard Schuknecht, and Walter P. Hölzle, who is also the company's Head of Business Development. According to the … [Read more...] about Akroswiss gets funding for development of midazolam nasal spray
Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division
DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for Iconovo. Acquisition of the Nordic marketing rights also marks the launch of a new division of Iconovo, Iconovo Pharma. The original deal included … [Read more...] about Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division
Pulmatrix says Cipla has breached a 2019 development agreement for Pulmazole intraconazole DPI
A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900). According to the company's business update, Pulmatrix recently notified Cipla that Cipla breached a 2019 development and commercialization … [Read more...] about Pulmatrix says Cipla has breached a 2019 development agreement for Pulmazole intraconazole DPI
Vectura to develop inhaled formulation of Inspira candidate for the treatment of COVID-19
Inhalation CDMO Vectura has signed an agreement with Inspira Pharmaceuticals to develop an inhaled formulation of a plant extract Inspira is developing for the treatment of COVID-19, the company said. Vectura will create a version of the IPX formulation to be delivered via Vectura's Fox vibrating mesh nebulizer for Phase 1 trials. Inspira is looking to raise £350,000 … [Read more...] about Vectura to develop inhaled formulation of Inspira candidate for the treatment of COVID-19